{"id":"NCT05310084","sponsor":"BioNTech SE","briefTitle":"Safety and Immunogenicity of BNT162b2 Coadministered With SIIV in Adults 18 Through 64 Years of Age","officialTitle":"A PHASE 3, RANDOMIZED, OBSERVER-BLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF BNT162b2 WHEN COADMINISTERED WITH SEASONAL INACTIVATED INFLUENZA VACCINE (SIIV) IN ADULTS 18 THROUGH 64 YEARS OF AGE","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2022-04-20","primaryCompletion":"2022-10-05","completion":"2022-10-05","firstPosted":"2022-04-04","resultsPosted":"2023-11-24","lastUpdate":"2024-06-12"},"enrollment":1134,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"PREVENTION"},"conditions":["SARS-CoV-2 Infection","COVID-19"],"interventions":[{"type":"BIOLOGICAL","name":"BNT162b2","otherNames":[]},{"type":"OTHER","name":"Placebo","otherNames":[]},{"type":"BIOLOGICAL","name":"Seasonal Inactivated Influenza Vaccine","otherNames":[]}],"arms":[{"label":"Coadministration Group","type":"EXPERIMENTAL"},{"label":"Separate Administration Group","type":"EXPERIMENTAL"}],"summary":"This study will assess the safety and immunogenicity of a fourth dose (booster) of BNT162b2 when coadministered with SIIV compared to separate administration of the vaccines when given 1 month apart (SIIV followed by BNT162b2), in participants who have received 3 prior doses of 30 Âµg BNT162b2, with the third dose being at least 90 days before Visit 1 (Day 1).\n\n* Healthy adults 18 through 64 years of age will be randomized 1:1 to either the co-administration group, or the separate administration group\n* The duration of the study for each participant will be approximately 2 months\n* There are 3 scheduled study visits each about 1 month apart\n* The study will be conducted in New Zealand and Australia.","primaryOutcome":{"measure":"Percentage of Participants With Local Reactions Within 7 Days After Vaccination 1","timeFrame":"Within 7 Days After Vaccination 1","effectByArm":[{"arm":"Coadministration Group","deltaMin":7.6,"sd":null},{"arm":"Separate Administration Group","deltaMin":0.5,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":26,"countries":["Australia","New Zealand"]},"refs":{"pmids":["37698774"],"seeAlso":["https://pmiform.com/clinical-trial-info-request?StudyID=C4591030"]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":564},"commonTop":["Injection site pain","Fatigue","Headache","Chills","COVID-19"]}}